ATE280226T1 - Genetische marker für brust und eierstockkrebs - Google Patents

Genetische marker für brust und eierstockkrebs

Info

Publication number
ATE280226T1
ATE280226T1 AT96913045T AT96913045T ATE280226T1 AT E280226 T1 ATE280226 T1 AT E280226T1 AT 96913045 T AT96913045 T AT 96913045T AT 96913045 T AT96913045 T AT 96913045T AT E280226 T1 ATE280226 T1 AT E280226T1
Authority
AT
Austria
Prior art keywords
specific
mutations
brca1
antibodies
diagnostic
Prior art date
Application number
AT96913045T
Other languages
English (en)
Inventor
Mary-Claire King
Lori Friedman
Beth Ostermeyer
Sarah Rowel
Eric Lynch
Csilla Szabo
Ming Lee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE280226T1 publication Critical patent/ATE280226T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96913045T 1995-04-19 1996-04-19 Genetische marker für brust und eierstockkrebs ATE280226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/425,061 US5622829A (en) 1993-12-08 1995-04-19 Genetic markers for breast, ovarian, and prostatic cancer
PCT/US1996/005621 WO1996033271A2 (en) 1995-04-19 1996-04-19 Genetic markers for breast and ovarian cancer

Publications (1)

Publication Number Publication Date
ATE280226T1 true ATE280226T1 (de) 2004-11-15

Family

ID=23684980

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913045T ATE280226T1 (de) 1995-04-19 1996-04-19 Genetische marker für brust und eierstockkrebs

Country Status (9)

Country Link
US (3) US5622829A (de)
EP (1) EP0821733B1 (de)
JP (1) JPH11503915A (de)
AT (1) ATE280226T1 (de)
AU (1) AU698800B2 (de)
CA (1) CA2217668C (de)
DE (1) DE69633664T2 (de)
ES (1) ES2231808T3 (de)
WO (1) WO1996033271A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014051A1 (en) * 2002-07-18 2004-01-22 Isis Pharmaceuticals Inc. Antisense modulation of breast cancer-1 expression
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
US5643722A (en) 1994-05-11 1997-07-01 Trustees Of Boston University Methods for the detection and isolation of proteins
US6210941B1 (en) 1997-06-27 2001-04-03 The Trustees Of Boston University Methods for the detection and isolation of proteins
US6403303B1 (en) * 1996-05-14 2002-06-11 Visible Genetics Inc. Method and reagents for testing for mutations in the BRCA1 gene
US6428955B1 (en) 1995-03-17 2002-08-06 Sequenom, Inc. DNA diagnostics based on mass spectrometry
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
US6083698A (en) * 1995-09-25 2000-07-04 Oncormed, Inc. Cancer susceptibility mutations of BRCA1
DE19629938C1 (de) * 1996-07-24 1997-11-27 Gsf Forschungszentrum Umwelt E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren
US5905026A (en) * 1996-08-27 1999-05-18 Cornell Research Foundation, Inc. Method of detecting expression of and isolating the protein encoded by the BRCA1 gene
AU4586697A (en) * 1996-09-20 1998-04-14 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
WO1998018966A1 (en) * 1996-10-31 1998-05-07 Jennifer Lescallett Primers for amplification of brca1
CA2270132A1 (en) * 1996-11-06 1998-05-14 Sequenom, Inc. Dna diagnostics based on mass spectrometry
US5965377A (en) * 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
EP0878552A1 (de) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
EP0983389A1 (de) * 1997-06-04 2000-03-08 Rijksuniversiteit te Leiden Testsatz und verfahren für den nachweis von einer rädisposition zum ovarial und brustkrebs
US7014993B1 (en) * 1997-08-21 2006-03-21 The Board Of Trustees Of The University Of Arkansas Extracellular serine protease
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6030832A (en) 1997-11-21 2000-02-29 Myriad Genetics, Inc. Carboxy-terminal BRCA1 interacting protein
WO1999057309A1 (en) * 1998-05-04 1999-11-11 Dako A/S Method and probes for the detection of chromosome aberrations
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
ES2233065T3 (es) 1998-07-13 2005-06-01 Board Of Regents, The University Of Texas System Utilizacion de anticuerpos anti-aminofosfolipidos para el tratamiento del cancer.
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
AU5128799A (en) * 1998-07-24 2000-02-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pb 39, a gene dysregulated in prostate cancer, and uses thereof
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
AU5460500A (en) 1999-06-04 2000-12-28 Massachusetts Institute Of Technology Compositions and methods for the screening of compounds to enhance or reduce apoptosis
US6306628B1 (en) * 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
US20030064372A1 (en) * 2000-06-22 2003-04-03 Bodnar Jackie S. Gene and sequence variation associated with lipid disorder
US6703204B1 (en) 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7465540B2 (en) * 2000-09-21 2008-12-16 Luminex Corporation Multiple reporter read-out for bioassays
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
WO2002099418A1 (en) * 2001-06-04 2002-12-12 Research Development Foundation Premalignant, serially-transplantable breast tissue lines and uses thereof
AU2003253629A1 (en) * 2002-06-07 2003-12-22 Myriad Genetics, Inc Large deletions in human brca1 gene and use thereof
BR0312692A (pt) 2002-07-15 2007-06-26 Univ Texas anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
JP5247031B2 (ja) 2004-01-22 2013-07-24 ユニバーシティー・オブ・マイアミ 局所用コエンザイムｑ１０製剤
EP2219672B1 (de) 2007-11-09 2016-02-17 Peregrine Pharmaceuticals, Inc. Anti-vegf-antikörper-zusammensetzungen und verfahren
US8167949B2 (en) * 2008-01-25 2012-05-01 Aesculap Implant Systems, Llc Hydrostatic interbody
CN111253483B (zh) * 2020-03-02 2021-07-30 江苏莱森生物科技研究院有限公司 一种抗brca1单克隆抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742000A (en) * 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
CA2064555A1 (en) * 1990-06-27 1991-12-28 Arnold J. Levine Probes for detecting mutant p53
US5597707A (en) * 1993-04-15 1997-01-28 Bristol-Myers Squibb Company Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer

Also Published As

Publication number Publication date
WO1996033271A3 (en) 1997-03-20
EP0821733A2 (de) 1998-02-04
US6512091B1 (en) 2003-01-28
EP0821733B1 (de) 2004-10-20
WO1996033271A2 (en) 1996-10-24
DE69633664T2 (de) 2006-02-23
JPH11503915A (ja) 1999-04-06
US5622829A (en) 1997-04-22
DE69633664D1 (de) 2004-11-25
CA2217668C (en) 1999-11-16
ES2231808T3 (es) 2005-05-16
CA2217668A1 (en) 1996-10-24
US5821328A (en) 1998-10-13
AU5566896A (en) 1996-11-07
AU698800B2 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
ATE280226T1 (de) Genetische marker für brust und eierstockkrebs
Raza-Egilmez et al. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia
EP1005540A4 (de) Ikk-beta proteines, nukleinsäuren und verfahren
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
DE60028970D1 (de) An her2 bindende peptidverbindungen
NO984415L (no) Peptider med antiproliferative egenskaper
DE69808743D1 (en) Netrinrezeptoren
WO2001014420A3 (en) Novel members of the plexin family and uses thereof
CA2281895A1 (en) Ikb kinases
DE69816467D1 (de) Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
JPH05502789A (ja) ムチンヌクレオチド
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
PT771352E (pt) Genes e operoes estruturais lkp pilina de haemophilus influenzae nao caracteristica
WO2003105773A3 (en) MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
US20200206322A1 (en) Treating cancer with cas endonuclease complexes
GB8929293D0 (en) C.difficile dna probes
Bala et al. Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
Grötzinger et al. A highly amplified mouse gene is homologous to the human interferon-responsive Sp100 gene encoding an autoantigen associated with nuclear dots
ES2189560B1 (es) Dna polimerasa k, nuevo marcador tumoral.
US8580929B2 (en) DNA sequence encoding a retinoic acid regulated protein
ATE207536T1 (de) Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6
ATE236250T1 (de) Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties